Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 28, 2006; 12(40): 6522-6526
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6522
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6522
Table 2 Response to therapy n (%)
| CR | PR | NC | PD | RR | 95% CI | |
| Overall | 0 | 16 (52) | 11 (35) | 4 (13) | 16 (52) | 33-70 |
| Prior chemotherapy | ||||||
| Yes | 0 | 4 (36) | 4 (27) | 3 (27) | 4 (36) | 11-69 |
| No | 0 | 12 (60) | 7 (35) | 1 (5) | 12 (60) | 36-81 |
| Liver | 2 (15) | 5 (39) | 5 (39) | 1 (8) | 7 (54) | |
| Lymph Nodes | 2 (8) | 12 (46) | 12 (46) | 0 | 14 (54) | |
| Peritoneal | 0 | 1 (33) | 1 (33) | 1 (33) | 1 (33) | |
| Ovary | 0 | 0 | 1 (50) | 1 (50) | 0 | |
| Lung | 0 | 1 (100) | 0 | 0 | 1 (100) | |
| Others | 0 | 1 (50) | 1 (50) | 0 | 1 (50) | |
- Citation: Imamura H, Ikeda M, Furukawa H, Tsujinaka T, Fujitani K, Kobayashi K, Narahara H, Kato M, Imamoto H, Takabayashi A, Tsukuma H. Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World J Gastroenterol 2006; 12(40): 6522-6526
- URL: https://www.wjgnet.com/1007-9327/full/v12/i40/6522.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i40.6522